Startup list · Europe
Biotech startups in Europe
Below are the top European biotech startups, ranked by total funding raised. Together the 50 companies on this list have raised a combined $32B. The strongest hubs are United Kingdom, Germany, France.
$32Bcombined funding · top 50
United Kingdomtop hub
50companies shown
1fast growing
Ranked by total funding · Updated 2026-06-26 · Source: Dealroom
| # | Company | Founded | HQ | Funding |
|---|---|---|---|---|
| 1 |
 J
Johnson & Johnson Innovative Medicine
Pharmaceutical company providing medicines for an array of health concerns in several therapeutic areas.
|
1953 | Beerse, Belgium | $2.7B |
| 2 |
 I
Isomorphic Labs$25M+ revenue
An artificial intelligence company to discover new drugs
|
2021 | London, United Kingdom | $2.7B |
| 3 |
 A
AstraZeneca
Biopharmaceutical solutions for major global diseases
|
1913 | Cambridge, United Kingdom | $2.1B |
| 4 |
 S
Sanofi
A global integrated healthcare leader discovers, develops and distributes therapeutic solutions
|
1973 | Paris, France | $2.0B |
| 5 |
 B
BioNTech$100M+ revenue
Develops personalized immunotherapies with a focus on cancer medicine
|
2008 | Mainz, Germany | $1.7B |
| 6 |
 O
Oxford Nanopore Technologies$100M+ revenue
Developing a new generation of nanopore-based electronic systems for analysis of single molecules
|
2005 | Oxford, United Kingdom | $1.3B |
| 7 |
 C
CureVac$100M+ revenue
Develops drugs that allow the human body to fight various diseases
|
2000 | Tübingen, Germany | $1.2B |
| 8 |
 A
ADC Therapeutics$100M+ revenue
Develops proprietary antibody drugs targeting cancer
|
2011 | Epalinges, Switzerland | $736M |
| 9 |
 I
Immunocore$100M+ revenue
TCR bispecific immunotherapies for cancer and infectious diseases
|
2008 | Milton, United Kingdom | $708M |
| 10 |
 B
Bicycle Therapeutics$25M+ revenue
Therapeutics based on its proprietary bicyclic peptide product platform
|
2009 | Cambridge, United Kingdom | $693M |
| 11 |
 E
Exscientia$25M+ revenue
Applying artificial intelligence and big data processing to accelerate discovery and development of drugs
|
2012 | Oxford, United Kingdom | $675M |
| 12 |
 I
ITM Radiopharma$100M+ revenue
Development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment
|
2004 | Garching bei München, Germany | $645M |
| 13 |
 C
Cheplapharm Arzneimittel
A Sustainable Platform for Specialty Pharma
|
1998 | Greifswald, Germany | $605M |
| 14 |
 T
Tubulis
Generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology
|
2019 | Planegg, Germany | $559M |
| 15 |
 I
InnovaFeed
Biotechnology company specializing in the breeding of insects for animal and plant food
|
2016 | Paris, France | $554M |
| 16 |
 C
CuspAI
Developing a platform to design new materials for sustainability and clean energy using use genAI, deep learning, and molecular simulation
|
2024 | Cambridge, United Kingdom | $530M |
| 17 |
 P
Pasqal
Full-stack neutral atom quantum computing systems
|
2019 | Palaiseau, France | $512M |
| 18 |
 I
Immatics biotechnologies$100M+ revenue
Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets
|
2000 | Tübingen, Germany | $478M |
| 19 |
 C
CellCentric
Oral p300/CBP inhibitor for targeted cancer therapy
|
2003 | Little Chesterford, United Kingdom | $474M |
| 20 |
 A
Apollo Therapeutics
Advancing a pipeline of potentially transformative therapeutic programs based on breakthrough discoveries
|
2016 | Stevenage, United Kingdom | $455M |
| 21 |
 B
BenevolentAI
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company
|
2013 | London, United Kingdom | $454M |
| 22 |
 G
Galecto | Damora Therapeutics
Biotechnology for mutant calreticulin-driven hematologic disorders, formerly known as Galecto
|
2011 | Copenhagen, Denmark | $440M |
| 23 |
 V
Verdiva Bio
Oral therapies for obesity and cardiometabolic disorders
|
2025 | London, United Kingdom | $411M |
| 24 |
 Q
Quanta Dialysis Technologies
Creates devices and services that improve dialysis experiences and every day living
|
2008 | Warwick, United Kingdom | $405M |
| 25 |
 C
COMPASS Pathways
Psilocybin-based therapies for treatment-resistant mental health conditions
|
2016 | London, United Kingdom | $394M |
| 26 |
 A
Artios Pharma
Next-generation DNA-repair targets advancing cancer treatment
|
2016 | Babraham, United Kingdom | $387M |
| 27 |
 A
ATAI Life Sciences
A biotechnology company pioneering mental health innovation
|
2018 | Berlin, Germany | $387M |
| 28 |
 A
Acerta Pharma$100M+ revenue
Clinical research on cancer and autoimmune diseases
|
2013 | Oss, Netherlands | $371M |
| 29 |
 O
Owkin$25M+ revenue
Collaborative research platform and unique AI drug development solutions that make precision medicine a reality
|
2016 | Paris, France | $368M |
| 30 |
 A
Alentis Therapeutics
Discovers and develops novel medications to treat advanced liver diseases
|
2019 | Allschwil, Switzerland | $366M |
| 31 |
 W
Windward BioFast growing
Biopharmaceutical company advancing treatments for oncology, immunology, and rare diseases with a focus on commercialization
|
2024 | Basel, Switzerland | $365M |
| 32 |
 F
F2G$100M+ revenue
Discovers and develops novel drugs for the treatment of life-threatening fungal diseases
|
1998 | Manchester, United Kingdom | $355M |
| 33 |
 H
Hemab Therapeutics
A biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders
|
2019 | Copenhagen, Denmark | $347M |
| 34 |
 J
Juvenescence
We're a clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan.
|
2016 | Dublin, Ireland | $341M |
| 35 |
 S
Symphogen$25M+ revenue
Develops antibodies for cancer treatments
|
2000 | Ballerup, Denmark | $339M |
| 36 |
 M
MindMaze
Digital neuro-therapeutics for brain health and recovery
|
2012 | Lausanne, Switzerland | $338M |
| 37 |
 N
Normax Biomed
Normax focus for 2022 is rapid growth in mRNA Vaccine R&D and manufacturing for sustainable pandemic preparedness
|
2020 | Cork, Ireland | $330M |
| 38 |
 A
Agomab
Developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues
|
2017 | Antwerp, Belgium | $327M |
| 39 |
 A
Atlas Agro
Atlas Agro is focus on developing and marketing sustainable solutions for crop protection, forestry, apiculture and public hygiene
|
2021 | Zug, Switzerland | $325M |
| 40 |
 A
Alvotech$100M+ revenue
Dedicated to broadening the availability and accessibility of biosimilars
|
2013 | Reykjavík, Iceland | $321M |
| 41 |
 A
ADCendo
A Copenhagen-based biotech company dedicated to developing highly differentiated antibody-drug conjugates (ADCs) for the treatment of underserved cancers
|
2017 | Copenhagen, Denmark | $321M |
| 42 |
 D
DNA Script
Transforming how molecular biology translates to human health, personalized medicine, and synthetic biology
|
2014 | Le Kremlin-Bicêtre, France | $312M |
| 43 |
 O
Orchard Therapeutics
Hematopoietic stem cell gene therapies for rare diseases
|
2015 | London, United Kingdom | $308M |
| 44 |
 X
Xanodyne
Integrated specialty pharmaceutical company focused on women’s healthcare and pain management
|
2000 | Newport, United Kingdom | $308M |
| 45 |
 A
Amolyt Pharma
Multinational group of biopharmaceutical companies developing drugs, proteins and peptides
|
2014 | Écully, France | $303M |
| 46 |
 H
Huma$25M+ revenue
Provides a digital health platform used for predictive care and research
|
2011 | London, United Kingdom | $298M |
| 47 |
 L
Leyden Labs
Mucosal protection platform for respiratory virus threats
|
2020 | Leiden, Netherlands | $291M |
| 48 |
 B
Biocartis$25M+ revenue
Develops diagnostic systems to reduce the cost and improve the efficacy of personalised medical treatments
|
2007 | Mechelen, Belgium | $283M |
| 49 |
 S
Spur Therapeutics
Gene therapies for Gaucher, Parkinson's, and cardiovascular diseases
|
2015 | Stevenage, United Kingdom | $276M |
| 50 |
 G
Gyroscope Therapeutics
Developing one-time gene therapies for retinal diseases
|
2016 | London, United Kingdom | $275M |
Track biotech in Europe
Get the full dataset — funding rounds, investors, signals and new entrants — in the Dealroom platform.
Book a demo